ReviewCancer management and research2015
The treatment landscape in thyroid cancer: a focus on cabozantinib.
Review in Cancer management and research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Decoding kinase-adverse event associations for small molecule kinase inhibitors.Nature communications · 2022Article
- Medullary thyroid carcinoma: recent advances in identification, treatment, and prognosis.Therapeutic advances in endocrinology and metabolism · 2021Review
- Neoadjuvant selpercatinib for advanced medullary thyroid cancer.Head & neck · 2021Article
- Novel Therapeutics in Radioactive Iodine-Resistant Thyroid Cancer.Frontiers in endocrinology · 2021Review
- Lenvatinib as a novel treatment for anaplastic thyroid cancer: A retrospective study.Oncology letters · 2018Article
- BPI-9016M, a c-Met inhibitor, suppresses tumor cell growth, migration and invasion of lung adenocarcinoma via miR203-DKK1.Theranostics · 2018Article
- The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer.Best practice & research. Clinical endocrinology & metabolism · 2017Review
- MiR-182 promotes cancer invasion by linking RET oncogene activated NF-κB to loss of the HES1/Notch1 regulatory circuit.Molecular cancer · 2017Article
- Practical management of adverse events associated with cabozantinib treatment in patients with renal-cell carcinoma.OncoTargets and therapy · 2017Review
- Lenvatinib for Anaplastic Thyroid Cancer.Frontiers in oncology · 2017Article
- Role of CDKN2C Copy Number in Sporadic Medullary Thyroid Carcinoma.Thyroid : official journal of the American Thyroid Association · 2016Article
- Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in the treatment of advanced thyroid cancer: a meta-analysis of randomized controlled trials.OncoTargets and therapy · 2016Article
- Medullary thyroid carcinoma - Adverse events during systemic treatment: risk-benefit ratio.Archives of endocrinology and metabolismReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Although patients with thyroid cancer generally fare well, there is a subset for which this is not necessarily true. Progress in understanding the molecular aberrations in thyroid cancer has led to a change in the management of these cases. Since 2011, four multikinase inhibitors (MKIs) have been approved by the US Food and Drug Administration for thyroid cancer - cabozantinib and vandetanib for medullary thyroid cancer and sorafenib and lenvatinib for differentiated thyroid cancer. This change in the treatment landscape has raised challenges for practitioners who may not be familiar with the use of MKIs or with the treatment and natural history of advanced thyroid cancer in general. This article reviews the epidemiology, molecular drivers, and initial treatment of patients with thyroid cancer and offers practical guidance to assist with the determination of when to appropriately start an MKI. As an example, cabozantinib and its efficacy are discussed in detail. Close monitoring is required for all patients on targeted agents to assess for adverse effects and response to therapy. An approach to managing drug-related adverse events is detailed. Since these drugs are not curative and have not yet proven to prolong overall survival, it is critical to weigh the risks and benefits of treatment at every visit. The potential value of changing to a different agent following failure of an MKI is also addressed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.